Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men

Hatim Kerniss, Philip Curman, Henning Olbrich, Khalaf Kridin, Rohin Francis, David M. Leistner, Uazman Alam, Ralf J. Ludwig

Open source

DOI
10.1016/j.ebiom.2026.106373
Published
2026-08
Container
eBioMedicine
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ebiom.2026.106373,
  title = {Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men},
  author = {Hatim Kerniss and Philip Curman and Henning Olbrich and Khalaf Kridin and Rohin Francis and David M. Leistner and Uazman Alam and Ralf J. Ludwig},
  year = {2026},
  journal = {eBioMedicine},
  doi = {10.1016/j.ebiom.2026.106373},
  url = {https://doi.org/10.1016/j.ebiom.2026.106373}
}

RIS

TY  - JOUR
TI  - Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men
AU  - Hatim Kerniss
AU  - Philip Curman
AU  - Henning Olbrich
AU  - Khalaf Kridin
AU  - Rohin Francis
AU  - David M. Leistner
AU  - Uazman Alam
AU  - Ralf J. Ludwig
PY  - 2026
JO  - eBioMedicine
DO  - 10.1016/j.ebiom.2026.106373
UR  - https://doi.org/10.1016/j.ebiom.2026.106373
ER  - 

APA

Kerniss, H., Curman, P., Olbrich, H., Kridin, K., Francis, R., Leistner, D. M., Alam, U., & Ludwig, R. J. (2026). Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men. eBioMedicine. https://doi.org/10.1016/j.ebiom.2026.106373

Source records